Abstract:Objective: To construct a kind of paclitaxel-loaded long-circulating nanoliposomes actively targeting lung tumor in order to improve the tissue distribution of paclitaxel in vivo, and to promote the safety and the anti-tumor efficacy of paclitaxel administration. Methods: The complex of arginine glycine-aspartic acid-e-amino hexanoic acid linker-palmitate (RGD-EACA-Pal) was synthesized by solid-phase synthesis method. The sterically stabilized liposome of paclitaxel (SSL-PTX) and the active lung cancer-targeting sterically stabilized liposome of paclitaxel (T-SSL-PTX) were prepared by thin film ultrasonication-dispersion method, respectively. The pharmacokinetics, tissue distribution and the anti-tumor effects of two different formulations of paclitaxel were evaluated after intravenous injection of taxol, SSL-PTX or T-SSL-PTX in tumor-bearing nude mice. The maximum tolerance doses (MTDs) of two different formulations of paclitaxel were determined in Kunming mice. Results: Transmission electron microscopy (TEM) image showed that both SSL-PTX and T-SSL-PTX shaped regularly round and dispersed uniformly, and these two particle sizes were (83.4±36.7) nm and (94.7±41.2) nm, respectively. The encapsulation efficiencies of both SSL-PTX and T-SSL-PTX were at or above 95%. In vivo, the circulation time of SSL-PTX or T-SSL-PTX was longer than taxol, and the pharmacokinetic parameters of SSL-PTX and T-SSL-PTX were similar. Tumor-targeting efficiency of T-SSL-PTX was better than that of SSL-PTX or taxol, as well as the tissue distribution of T-SSL-PTX in normal organs was at a relatively low level as compared with that of SSL-PTX or taxol, in contribution to RGD specifically targeting tumors. The MTDs of SSL-PTX and T-SSL-PTX were higher than that of taxol. Compared with SSL-PTX and taxol with the same dose of paclitaxel, the anti-tumor efficacy of T-SSL-PTX was improved significantly (P＜0.05); and the mice received T-SSL-PTX therapy with a longer interval or at a lower dose also achieved significant tumor growth retardation.Conclusion: The lung cancer-targeting long-circulating nanoliposomes of paclitaxel may increase the safety and anti-tumor efficacy of paclitaxel through improving its pharmacokinetics and tissue distribution in vivo. DOI:10.3781/j.issn.1000-7431.2011.03.004

Correction to "α3β1 Integrin-Targeting Polymersomal Docetaxel As an Advanced Nanotherapeutic for Nonsmall Cell Lung Cancer Treatment".

<sub>3</sub><sub>1</sub> Integrin-Targeting Polymersomal Docetaxel as an Advanced Nanotherapeutic for Nonsmall Cell Lung Cancer Treatment

Correction to "α 3 β 1 Integrin-Targeting Polymersomal Docetaxel as an Advanced Nanotherapeutic for Nonsmall Cell Lung Cancer Treatment"

The Anti-Tumor Effects of Lung Cancer-Targeting Long-Circulating Paclitaxel-Containing Liposomes

Targeted Chemotherapy for Subcutaneous and Orthotopic Non-Small Cell Lung Tumors with Cyclic RGD-functionalized and Disulfide-Crosslinked Polymersomal Doxorubicin

Integrin-targeting Disulfide-Crosslinked Micellar Docetaxel Eradicates Lung and Prostate Cancer Patient-Derived Xenografts.

Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.

Medium-chain Triglyceride-Stabilized Docetaxel-Loaded HSA Nanoparticles Effectively Inhibited Metastatic Non-Small Cell Lung Cancer

Enhanced in Vivo Antitumor Efficacy of Dual-Functional Peptide-Modified Docetaxel Nanoparticles Through Tumor Targeting and Hsp90 Inhibition.

Antitumor efficiency of D-alpha-tocopheryl polyethylene glycol 1000 succinate-b-poly(epsilon-caprolactone-ran-lactide) nanoparticle-based delivery of docetaxel in mice bearing cervical cancer.

NGR-modified Ph-Sensitive Liposomes for Controlled Release and Tumor Target Delivery of Docetaxel.

Nanoformulated Paclitaxel and AZD9291 Synergistically Eradicate Non-Small-cell Lung Cancers in Vivo

The Anti-Tumor and Immunomodulatory Effects of PLGA-Based Docetaxel Nanoparticles in Lung Cancer: The Potential Involvement of Necroptotic Cell Death through Reactive Oxygen Species and Calcium Build-Up

Current Development in Nanoformulations of Docetaxel

Current development in nanoformulations of docetaxel.

How Nanotechnology Can Enhance Docetaxel Therapy

Antitumor Efficiency of D-α-Tocopheryl Polyethylene Glycol 1000 Succinate-b-Poly(ε-caprolactone-<I>ran</I>-lactide) Nanoparticle-Based Delivery of Docetaxel in Mice Bearing Cervical Cancer

Solid Lipid Nanoparticle Formulations of Docetaxel Prepared with High Melting Point Triglycerides: In Vitro and in Vivo Evaluation

Tumour Microenvironment-Responsive Lipoic Acid Nanoparticles for Targeted Delivery of Docetaxel to Lung Cancer

Docetaxel-loaded exosomes for targeting non-small cell lung cancer: preparation and evaluation in vitro and in vivo

Enhanced Antiproliferative and Apoptosis Effect of Paclitaxel-Loaded Polymeric Micelles Against Non-Small Cell Lung Cancers